<DOC>
	<DOCNO>NCT00080275</DOCNO>
	<brief_summary>The purpose 24 week study compare effectiveness safety different dos Niacin ER/Simvastatin ( NS ) subject elevate fat level blood ( dyslipidemia ) . At least 600 subject similar medical condition take part study .</brief_summary>
	<brief_title>Evaluation Safety &amp; Efficacy Combination Niacin ER &amp; Simvastatin Patients With Dyslipidemia ( OCEANS )</brief_title>
	<detailed_description>Objectives : To evaluate safety efficacy combination product niacin ER simvastatin ( NS ) patient primary type II dyslipidemia descriptively compare flush rate two Titration Schedules NS .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient primary Type II hyperlipidemia mixed dyslipidemia . If patient currently take lipid modify medication Zocor &amp; he/she willing discontinue medication LDLC level and/or non HDLC level normal . Reasonable compliance standard cholesterollowering diet minimum 4 week prior screen duration study . Patient allergy , hypersensitivity , intolerance niacin , statin , derivative . HbA1c â‰¥ 9 % diabetic patient</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Niacin</keyword>
	<keyword>Statin</keyword>
	<keyword>Zocor</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Stroke</keyword>
	<keyword>High-Density Lipoprotein Cholesterol</keyword>
	<keyword>Low-Density Lipoprotein Cholesterol</keyword>
	<keyword>Lipoprotein</keyword>
	<keyword>Lipid</keyword>
	<keyword>Niacin ER/simvastatin</keyword>
	<keyword>Total Cholesterol</keyword>
	<keyword>Triglycerides</keyword>
</DOC>